Abbott Laboratories Gains 0.1% as Trading Volume Slides to 240th Rank Analysts Diverge on Diabetes Business Outlook

Abbott Laboratories (NYSE:ABT) closed September 5, 2025, , , . The stock ranked 240th in trading volume among listed equities. Recent analyst activity has focused on the company’s diabetes division, which remains a core growth driver despite challenges in its diagnostics segment.

Piper Sandler reiterated an Overweight rating for Abbott, . The firm highlighted untapped potential in Abbott’s diabetes business, . This innovation, combined with a partnership with , is seen as undervalued by current market estimates. , .

Analyst responses to the revised outlook were mixed. , , . , citing strong performance in the MedTech division, .

Backtesting a strategy involving daily rebalancing of a top-500-by-volume portfolio requires clarifying key parameters. These include defining the stock universe (e.g., NYSE, NASDAQ, AMEX or indices like Russell 1000), specifying entry/exit timing (close-to-close, close-to-open), and determining whether to account for transaction costs or slippage. Once these details are confirmed, the backtest can proceed to evaluate performance metrics against the outlined framework.